Oculis Holding AG (ICE:OCS)
Iceland · Delayed Price · Currency is ISK | Market Cap | 96.62B -15.4% |
| Revenue (ttm) | 182.79M +53.5% |
| Net Income | -12.34B |
| EPS | -215.95 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,499 |
| Open | 1,590.00 |
| Previous Close | 1,570.00 |
| Day's Range | 1,570.00 - 1,610.00 |
| 52-Week Range | 1,290.00 - 4,180.00 |
| Beta | 0.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological da... [Read more]
Financial Performance
In 2025, Oculis Holding AG's revenue was 1.20 million, an increase of 74.78% compared to the previous year's 686,000. Losses were -98.96 million, 15.4% more than in 2024.
Financial numbers in CHF Financial StatementsNews
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today ...
Oculis price target lowered to $20 from $23 at JPMorgan
JPMorgan lowered the firm’s price target on Oculis (OCS) to $20 from $23 and keeps an Overweight rating on the shares.
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
Oculis price target lowered to $32 from $35 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Oculis (OCS) to $32 from $35 and keeps a Buy rating on the shares. The firm adjusted targets for several…
Oculis to acquire development, commercial rights to Privosegtor from Accure
Oculis (OCS) and Accure Therapeutics announced that Oculis and Accure have entered into an asset purchase agreement whereby, upon closing, Oculis will acquire all of Accure’s worldwide development and...
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company
ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations t...
Oculis reports Q2 EPS (16c), consensus (38c)
Riad Sherif, Chief Executive Officer of Oculis (OCS), stated, “We continue to advance and expand the Privosegtor neuroprotection franchise, with PIONEER-1 on track in global site activations and posit...
Oculis Reports Q2 2026 Financial Results and Provides Company Update
ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant ...
Oculis Holding AG Earnings release: Q2 2026
Oculis Holding AG released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Oculis gets FDA pre-IND feedback regarding Privosegtor clinical development plan
Oculis (OCS) announced FDA pre-IND feedback regarding Privosegtor’s clinical development plan in acute multiple sclerosis relapses. Privosegtor is a peptoid small-molecule candidate with potential neu...
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
ZUG, Switzerland, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to a...
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
ZUG, Switzerland, July 2, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophth...
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to ad...
Oculis Holding AG Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Following a setback in the DIAMOND trials, resources are now focused on advancing Privosegtor in neuro-ophthalmology and Licaminlimab in dry eye, both with innovative clinical strategies. Privosegtor targets large unmet needs and market potential, while a strong cash position supports ongoing development.
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
ZUG, Switzerland, June 9, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical ne...
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant u...
Oculis Holding AG Slides: Study update presentation
Oculis Holding AG has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.
Oculis price target lowered to $23 from $42 at JPMorgan
JPMorgan lowered the firm’s price target on Oculis (OCS) to $23 from $42 and keeps an Overweight rating on the shares. The firm cites the negative Phase 3 diabetic macular…
Oculis Holding AG Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Oculis Holding AG (NASDAQ: OCS) or certain of its executive officers violated federal securities laws. The in...
Oculis price target lowered to $38 from $49 at Baird
Baird lowered the firm’s price target on Oculis (OCS) to $38 from $49 and keeps an Outperform rating on the shares. The firm updated its model following news its OCS-01…
Oculis price target lowered to $38 from $49 at Baird
Baird lowered the firm’s price target on Oculis (OCS) to $38 from $49 and keeps an Outperform rating on the shares.
Oculis price target lowered to $35 from $44 at BofA
BofA lowered the firm’s price target on Oculis (OCS) to $35 from $44 and keeps a Buy rating on the shares. The firm removed OCS-01 in DME from its model…
Oculis Holding AG Slides: Corporate presentation
Oculis Holding AG has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Oculis price target lowered to $38 from $46 at Needham
Needham lowered the firm’s price target on Oculis (OCS) to $38 from $46 and keeps a Buy rating on the shares.
Oculis price target lowered to $45 from $75 at Guggenheim
Guggenheim lowered the firm’s price target on Oculis (OCS) to $45 from $75 and keeps a Buy rating on the shares after the company reported that the Phase 3 DIAMOND-1…